Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions
Thomas SM, Pham B, Lee T, Lillie E, Hamid JS, Agarwal A, Sharpe JP, Scott A, Warren R, Brahmbhatt R, Macdonald E, Straus S, Tricco AC, Richter TA; Verbrugghe S, Janoudi G, Lee K
Record ID 32018002199
English
Original Title:
Anti-vascular endothelial growth factor drugs for retinal conditions
Authors' objectives:
The objective of this report was to evaluate the comparative efficacy, safety, and cost-effectiveness of anti-VEGF drugs for treating patients with the following retinal conditions:
- Neovascular (wet) age-related macular degeneration (AMD)
- Diabetic macular edema (DME)
- Macular edema due to retinal vein occlusion (RVO)
- Choroidal neovascularization (CNV) secondary to pathologic myopia (PM).
Details
Project Status:
Completed
URL for protocol:
https://cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGF_Protocol_e.pdf
Year Published:
2016
URL for published report:
https://cadth.ca/sites/default/files/pdf/TR0009_Anti-VEGF_TR_Science_Report.pdf
URL for additional information:
https://cadth.ca/anti-vascular-endothelial-growth-factor-drugs-retinal-conditions
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Canada
MeSH Terms
- Retinal Diseases
- Macular Degeneration
- Wet Macular Degeneration
- Macular Edema
- Myopia, Degenerative
- Choroidal Neovascularization
- Angiogenesis Inhibitors
- Diabetic Retinopathy
- Vascular Endothelial Growth Factor A
- Ranibizumab
- Bevacizumab
Keywords
- Age-related macular degeneration
- Diabetic macular edema
- Macular edema
- Retinal vein occlusion
- Choroidal neovasculariatiokn
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
<p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.